High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

American Journal of Medical Genetics, Part A

Volumn 161, Issue 8, 2013, Pages 1897-1903

  Dziembowska, Magdalena ^a   Pretto, Dalyir I ^b   Janusz, Aleksandra ^a   Kaczmarek, Leszek ^a   Leigh, Mary Jacena ^b,c   Gabriel, Nielsen ^b   Durbin Johnson, Blythe ^b   Hagerman, Randi J ^b,c   Tassone, Flora ^b,c  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FXS; Metalloproteinases; Minocycline; MMP 9

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GELATINASE B; MINOCYCLINE; PLACEBO;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MOSAICISM; NERVE CELL PLASTICITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SOUTHERN BLOTTING; SYNAPTIC TRANSMISSION; ZYMOGRAPHY;

FXS; METALLOPROTEINASES; MINOCYCLINE; MMP-9;

ADOLESCENT; ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MATRIX METALLOPROTEINASE 9; MICE; MINOCYCLINE; NEURONS;

EID: 84880746947     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36023     Document Type: Article

References (36)

1. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
2. Berry-Kravis E, Knox A, Hervey C. 2011. Targeted treatments for fragile X syndrome. J Neurodev Disord 3:193-210.
3. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. 2009. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46:94-102.
4. Bozdagi O, Nagy V, Kwei KT, Huntley GW. 2007. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol 98:334-344.
5. Bramham CR, Wells DG. 2007. Dendritic mRNA: Transport, translation and function. Nat Rev Neurosci 8:776-789.
6. Bruno MA, Cuello AC. 2006. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 103:6735-6740.
7. Chen X, Ma L, Jiang Y, Chen S, Zhu C, Liu M, Ma X, Zhu D, Liu Y, Peng F, Wang Q, Pi R. 2012. Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis. Eur J Pharmacol 686:124-129.
8. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. 2011. The prospects of minocycline in multiple sclerosis. J Neuroimmunol 235:1-8.
9. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH. 2007. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32:2393-2404.
10. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB. 2011. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-261.
11. Dziembowska M, Milek J, Janusz A, Rejmak E, Romanowska E, Gorkiewicz T, Tiron A, Bramham CR, Kaczmarek L. 2012. Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci 32:14538-14547.
12. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, Hagerman PJ, Stenzel TT, Hadd A, Latham GJ, Tassone F. 2010. A novel FMR1 PCR method for the routine detection of low-abundance expanded alleles and full mutations in Fragile X syndrome. Clin Chem 56:399-408.
13. Garner SE, Eady EA, Popescu C, Newton J, Li WA. 2003. Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev CD002086.
14. Gupta RK, Awasthi R, Rathore RK, Verma A, Sahoo P, Paliwal VK, Prasad KN, Pandey CM, Narayana PA. 2012. Understanding epileptogenesis in calcified neurocysticercosis with perfusion MRI. Neurology 78:618-625.
15. Guy W, Bonato Re. 1970. CGI: Clinical global impressions. In: Manual for the ECDEU Assessment Battery.2. Rev ed. Chevy Chase, MD: National Institute of Mental Health. pp 12-1-12-6.
16. Harris SW, Hessl D, Goodlin-Jones B, Ferranti J, Bacalman S, Barbato I, Tassone F, Hagerman PJ, Herman H, Hagerman RJ. 2008. Autism profiles of males with Fragile X syndrome. Am J Ment Retard 113:427-438.
17. Kalonia H, Mishra J, Kumar A. 2012. Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats. Neurotox Res 22:310-320.
18. Kriz J, Nguyen MD, Julien JP. 2002. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10:268-278.
19. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. 2013. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with Fragile X Syndrome. J Dev Behav Pediatr 34:147-155.
20. Mannello F. 2003. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 49:339-340.
21. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332.
22. Meighan PC, Meighan SE, Davis CJ, Wright JW, Harding JW. 2007. Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses. J Neurochem 102:2085-2096.
23. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K, Medvedev N, Wilczek E, De Roo M, Zuschratter W, Muller D, Wilczynski GM, Mozrzymas JW, Stewart MG, Kaczmarek L, Wlodarczyk J. 2011. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 124:3369-3380.
24. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley GW. 2006. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 26:1923-1934.
25. Okulski P, Jay TM, Jaworski J, Duniec K, Dzwonek J, Konopacki FA, Wilczynski GM, Sanchez-Capelo A, Mallet J, Kaczmarek L. 2007. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry 62:359-362.
26. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. 2010. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10:91.
27. Siller SS, Broadie K. 2011. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 4:673-685.
28. Szklarczyk A, Lapinska J, Rylski M, McKay RD, Kaczmarek L. 2002. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 22:920-930.
29. Tassone F, Iong KP, Tong TH, Lo J, Gane WL, Berry-Kravis E, Nguyen D, Mu YL, Laffin J, Bailey DB, Hagerman RJ. 2012. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 4:100-113.
30. Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. 2008. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn 10:43-49.
31. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, Ethell IM, Nguyen DV. 2010. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 115:433-443.
32. Verma A, Prasad KN, Nyati KK, Singh SK, Singh AK, Paliwal VK, Gupta RK. 2011. Association of MMP-2 and MMP-9 with clinical outcome of neurocysticercosis. Parasitology 138:1423-1428.
33. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100:10483-10487.
34. Wang XB, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. 2008. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci U S A 105:19520-19525.
35. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L. 2008. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 180:1021-1035.
36. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.